2023 Partners:

Get in touch if you would like to partner and learn more about our bespoke sponsorship opportunities for 2024


Repair Biotechnologies

Expertise Partner

Repair Biotechnologies is a preclinical biotechnology company that develops drugs based on the REPAIR platform for clearance of toxic free intracellular cholesterol, aimed at reversal of NASH, atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.



Expertise Partner 

In Gero, we use physics-based generative models on massive human health record datasets, combined with AI-guided drug design, to develop meaningful interventions for aging and age-related diseases.


Maxwell logo - High Res

Maxwell Biosciences 

Expertise Partner 

Maxwell Biosciences has developed the CLAROMER® immunorejuvenation drug discovery platform and is entering human trials in 2024. Animal studies show that the first anti-inflammatory lead drug candidate (MXB-22,510) is a world-first “One drug for MANY bugs” anti-infective, able to successfully treat a broad spectrum of chronic infections associated with aging. Maxwell has received highly encouraging FDA feedback on MXB-22,510’s novel mechanism of action, as well as fungicidal, bactericidal, virucidal and safety properties.



Expertise Partner 

MYMD-1® has demonstrated the potential to slow the aging process
and extend healthy lifespan. The product is being evaluated in Phase
2 studies for sarcopenia/frailty, a result of the aging process, as well
as early-stage trials for rheumatoid arthritis (RA), with the potential to
expand into other applications.